SCHEMBL4157984

SCHEMBL4157984

COc1ccc([C@H]2C[N]CCO2)cc1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ SLC6A2 P23975 1/20 0.42
▸ SLC6A4 P31645 1/20 0.42
▸ SLC6A3 Q01959 1/20 0.42
▸ MAOB P27338 4/20 0.41
▸ NPC1 O15118 2/20 0.41
▸ MAPT P10636 2/20 0.41
▸ RAB9A P51151 2/20 0.41
▸ PTPN1 P18031 1/20 0.40
▸ KDM1A O60341 2/20 0.40
▸ MAOA P21397 1/20 0.40
▸ CYP3A4 P08684 1/20 0.38
▸ CYP19A1 P11511 1/20 0.38
▸ CA12 O43570 1/20 0.37
▸ CA1 P00915 1/20 0.37
▸ CA2 P00918 1/20 0.37
▸ CA7 P43166 1/20 0.37
▸ CA9 Q16790 1/20 0.37
▸ CA14 Q9ULX7 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4176881 1.00 SLC6A2 (0.42) SLC6A2SLC6A4SLC6A3MAOBNPC1
SCHEMBL4165135 1.00 SLC6A2 (0.42) SLC6A2SLC6A4SLC6A3MAOBNPC1
SCHEMBL4973937 0.81 LMNA (0.45) NPC1RAB9AKDM1ACYP3A4CYP19A1
SCHEMBL4973947 0.81 LMNA (0.45) NPC1RAB9AKDM1ACYP3A4CYP19A1
SCHEMBL5654186 0.81 MAOB (0.37) MAOBRAB9AALDH1A1SMN1; SMN2
SCHEMBL4972606 0.81 MAOB (0.37) MAOBRAB9AALDH1A1SMN1; SMN2
SCHEMBL8862481 0.80 KCNH2 (0.43) MAOBNPC1RAB9AMAOACYP3A4
SCHEMBL5651374 0.80 ALDH1A1 (0.49) ALDH1A1
SCHEMBL4973210 0.80 NISCH (0.40) KDM1A
SCHEMBL4973215 0.80 NISCH (0.40) KDM1A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-15 — — US claimed
US-20090099175-A1 Phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2009-04-16 — — US disclosed
EP-1991540-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS Amgen Inc. (US) 2008-11-19 — — EP disclosed
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors MEMORY PHARMACEUTICALS CORPORATION 2007-11-15 — — US disclosed
WO-2007098214-A1 CINNOLINE DERIVATIVES AS PHOSPHODIESTERASE 10 INHIBITORS AMGEN INC. (US) 2007-08-30 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20070265270-A1 Cinnoline derivatives as phosphodiesterase 10 inhibitors PDE7A, PDE10A, PDE7B SLC6A2 1573/4885SLC6A4 1871/4885SLC6A3 242/4885
US-20090099175-A1 Phosphodiesterase 10 inhibitors PDE7A, PDE7B, PDE10A SLC6A2 1493/4885SLC6A4 1912/4885SLC6A3 259/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback